Pfizer news from FiercePharma
NewsSPOTLIGHT: Feds tout Chantix in stop-smoking guidelines
The federal government's new stop-smoking guidelines recommend Chantix, the Pfizer drug that has been linked to depression and suicidal behavior, saying that the drug's effectiveness outweighs those Read more...
BMS: Buyer or buyout target?
Market-watchers love to speculate. Their latest topic? Bristol-Myers Squibb, which has been paring away its "non-core" businesses over the last few months. Most recently, Bristol agreed to Read more...
New Canadian rules to delay big generics
Generics makers are up in arms over proposed patent rules in Canada. The drug copycats say the rules will delay generic Lipitor and several other blockbusters by as much as two years. (Can you hear Read more...
Pfizer starts settling Celebrex claims
Pfizer is starting to settle the thousands of lawsuits over painkillers Celebrex and Bextra, the Wall Street Journal reports. Three groups of plaintiffs who allege that the meds caused heart attacks Read more...
Make generic-switching bonuses illegal?
Should insurers be allowed to reward docs who switch patients to generics? That debate is going public in Colorado, where legislators have proposed a bill that would prohibit the practice. On the Read more...
DTC hearing has high-powered guest list
Hail, hail the gang's all here...at the House Subcommittee on Oversight and Investigations hearing on direct-to-consumer ads. Next week, Rep. Bart Stupak will preside over testimony from Pfizer, Read more...
SPOTLIGHT: Pfizer to turn Esperion back to Newton
Pfizer snapped up Esperion Therapeutics four years ago, hip to its cholesterol candidates, but shut it down last year. Now, Esperion will relaunch as a private company with its previous leader, Roger Read more...
Office upholds Pfizer's Lipitor patent
Pfizer is breathing a big sigh of relief. The U.S. Patent & Trademark Office has said it will confirm the drugmaker's basic patent on the blockbuster Lipitor drug. The office had been Read more...
Letters show Nigeria OK'd Pfizer trial
Pfizer is back at the negotiating table with the Nigerian state of Kano in an attempt to finally settle claims about a meningitis drug trial the government contends was conducted illegally. The Read more...
ALSO NOTED: Novo Nordisk creating 400 NJ jobs; Schering to sell off animal products;
> GlaxoSmithKline is acquiring Cambridge, MA-based Sirtris Pharmaceuticals for $720 million. GSK will pay $22.50 per share for the company. Read more...
| Press ReleasesPfizerAnnounces Discontinuation of Phase III Clinical Trial for Patients with Advanced Melanoma Pfizer Inc. (PFE) Announces Discontinuation of Phase III Clinical Trial for Patients with Advanced Melanoma 4/2/2008 NEW YORK--(BUSINESS WIRE)--Pfizer Inc announced today the discontinuation of a Read more... Tacere Therapeutics Enters Collaboration and License Agreement With Pfizer Tacere Therapeutics Enters Collaboration and License Agreement With Pfizer SAN JOSE, Calif., Jan 07, 2008 -- Tacere Therapeutics, Inc., an RNA interference (RNAi)-based therapeutics developer, Read more... Pfizer and Taisho Pharmaceutical Finalize Deal on Schizophrenia Drug; Pfizer to Pay Initial $22M Pfizer and Taisho Pharmaceutical Finalize Deal on Schizophrenia Drug; Pfizer to Pay Initial $22M NEW YORK & TOKYO--(BUSINESS WIRE)--Pfizer Inc [Headquarter: New York, NY, USA, CEO: Jeffrey B. Read more... PRESS RELEASE: Pfizer to Acquire CovX to Extend Biotherapeutics Investment Pfizer to Acquire CovX to Extend Biotherapeutics Investment Acquisition Will Provide Innovative Biotherapeutics Technology Platform and Complementary Product Candidates in Oncology and Diabetes NEW Read more... PRESS RELEASE: Pfizer and Adolor Enter into Exclusive Worldwide Collaboration to Develop and Commercialize Novel Pain Compounds Pfizer and Adolor Enter into Exclusive Worldwide Collaboration to Develop and Commercialize Novel Pain Compounds NEW YORK & EXTON, Pa. -- Dec 5, 2007 - Pfizer and Adolor Corporation announced Read more... |
Get more Pfizer coverage at:
Paid Research Reports
- Pipeline Insight: Nosocomial Vaccines - Minefield or Goldmine?
- Drug Approval Trends at the FDA and EMEA: Process improvements, heightened scrutiny and industry response
- Biotech 2008 – life sciences industry report (online & print)
- Is there a market for alcoholism pharmacotherapies?
- New report provides Rheumatoid Arthritis market insight